- Trials with a EudraCT protocol (298)
- Paediatric studies in scope of Art45 of the Paediatric Regulation (49)
298 result(s) found for: Remission of Ulcerative Colitis AND Colitis.
Displaying page 6 of 15.
| EudraCT Number: 2015-000480-14 | Sponsor Protocol Number: MLN0002SC-3027 | Start Date*: 2016-03-21 | |||||||||||
| Sponsor Name:Takeda Development Centre Europe, Ltd. | |||||||||||||
| Full Title: A Phase 3 Randomized, Double-Blind, Placebo-Controlled Study, with a Vedolizumab IV Reference Arm, to Evaluate the Efficacy and Safety of Vedolizumab Subcutaneous as Maintenance Therapy in Subjects... | |||||||||||||
| Medical condition: Ulcerative Colitis | |||||||||||||
|
|||||||||||||
| Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
| Trial protocol: NL (Completed) SK (Completed) CZ (Completed) BG (Completed) GB (Completed) DE (Completed) BE (Completed) SE (Completed) DK (Completed) LT (Completed) ES (Completed) HU (Completed) RO (Completed) HR (Completed) IT (Completed) | |||||||||||||
| Trial results: View results | |||||||||||||
| EudraCT Number: 2009-013680-19 | Sponsor Protocol Number: 541/09 | Start Date*: 2009-12-18 | ||||||||||||||||
| Sponsor Name:POLICLINICO UNIVERSITARIO AGOSTINO GEMELLI | ||||||||||||||||||
| Full Title: Phase II, Open, Monocenter Study to investigate the efficacy of Propionyl-L-carnitine (ST 261) Colon Release Tablets in Patients Affected by Inflammatory Bowel Disease (IBD) under Oral Stable Trea... | ||||||||||||||||||
| Medical condition: IBD | ||||||||||||||||||
|
||||||||||||||||||
| Population Age: Adults, Elderly | Gender: Male, Female | |||||||||||||||||
| Trial protocol: IT (Completed) | ||||||||||||||||||
| Trial results: (No results available) | ||||||||||||||||||
| EudraCT Number: 2022-001683-10 | Sponsor Protocol Number: BIRD2022001 | Start Date*: 2022-11-28 | |||||||||||
| Sponsor Name:BIRD vzw (Belgian IBD Research and Development) | |||||||||||||
| Full Title: ChAracterizing the Remission status in patients with Ulcerative Colitis treated by 5-ASA | |||||||||||||
| Medical condition: Ulcerative colitis | |||||||||||||
|
|||||||||||||
| Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
| Trial protocol: BE (Completed) | |||||||||||||
| Trial results: (No results available) | |||||||||||||
| EudraCT Number: 2012-003974-18 | Sponsor Protocol Number: VB-201-064 | Start Date*: 2012-12-10 | |||||||||||
| Sponsor Name:Vascular Biogenics Ltd. | |||||||||||||
| Full Title: A Randomized, Double-Blind, 12-Week, Placebo-Controlled Study Followed by a 12-Week Extension Phase Without Placebo to Evaluate the Efficacy and Safety of Oral VB-201 in Subjects with Mild to Moder... | |||||||||||||
| Medical condition: Mild to Moderate Ulcerative Colitis | |||||||||||||
|
|||||||||||||
| Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
| Trial protocol: HU (Completed) BG (Completed) | |||||||||||||
| Trial results: View results | |||||||||||||
| EudraCT Number: 2018-000930-37 | Sponsor Protocol Number: M15-722 | Start Date*: 2018-12-21 | |||||||||||
| Sponsor Name:AbbVie Deutschland GmbH & Co. KG | |||||||||||||
| Full Title: A Multicenter, Single-Arm, Open-Label Study to Investigate the Efficacy and Safety of Ravagalimab (ABBV-323) in Subjects with Moderate to Severe Ulcerative Colitis Who Failed Prior Therapy | |||||||||||||
| Medical condition: Ulcerative Colitis | |||||||||||||
|
|||||||||||||
| Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
| Trial protocol: NL (Prematurely Ended) DE (Prematurely Ended) GB (GB - no longer in EU/EEA) FR (Prematurely Ended) ES (Completed) HU (Completed) IT (Prematurely Ended) | |||||||||||||
| Trial results: View results | |||||||||||||
| EudraCT Number: 2016-001158-16 | Sponsor Protocol Number: B7541002 | Start Date*: 2016-12-05 | |||||||||||
| Sponsor Name:Pfizer Inc. 235 East 42nd Street, New York, NY 10017 | |||||||||||||
| Full Title: A PHASE 2A, MULTICENTER, SINGLE ARM, OPEN-LABEL, TWO-STAGE, STUDY TO EVALUATE THE EFFICACY, SAFETY, TOLERABILITY AND PHARMACOKINETICS OF PF-06480605 IN SUBJECTS WITH MODERATE TO SEVERE ULCERATIVE C... | |||||||||||||
| Medical condition: Ulcerative colitis (UC) | |||||||||||||
|
|||||||||||||
| Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
| Trial protocol: BE (Completed) PL (Completed) NL (Completed) IT (Completed) | |||||||||||||
| Trial results: View results | |||||||||||||
| EudraCT Number: 2017-002274-39 | Sponsor Protocol Number: A3921288 | Start Date*: 2017-12-08 | |||||||||||
| Sponsor Name:Pfizer Inc. | |||||||||||||
| Full Title: A PHASE 3B/4, MULTI-CENTER, DOUBLE-BLIND, RANDOMIZED, PARALLEL GROUP STUDY OF TOFACITINIB (CP-690,550) IN SUBJECTS WITH ULCERATIVE COLITIS IN STABLE REMISSION | |||||||||||||
| Medical condition: Ulcerative colitis | |||||||||||||
|
|||||||||||||
| Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
| Trial protocol: SK (Prematurely Ended) CZ (Prematurely Ended) BE (Completed) HU (Completed) NL (Prematurely Ended) GB (GB - no longer in EU/EEA) AT (Prematurely Ended) ES (Prematurely Ended) IT (Completed) | |||||||||||||
| Trial results: View results | |||||||||||||
| EudraCT Number: 2020-002833-13 | Sponsor Protocol Number: AMT-101-203 | Start Date*: 2021-02-05 | |||||||||||
| Sponsor Name:Applied Molecular Transport Inc. | |||||||||||||
| Full Title: A Randomized, Placebo-controlled, Double-blind, Parallel-group, Exploratory, Phase 2 Study of the Efficacy and Safety of Oral AMT-101 in Combination with Adalimumab in Subjects with Moderate to Sev... | |||||||||||||
| Medical condition: Ulcerative Colitis | |||||||||||||
|
|||||||||||||
| Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
| Trial protocol: NL (Completed) PL (Completed) | |||||||||||||
| Trial results: (No results available) | |||||||||||||
| EudraCT Number: 2018-001605-93 | Sponsor Protocol Number: 3151-201-008 | Start Date*: 2019-07-01 | |||||||||||
| Sponsor Name:AstraZeneca AB | |||||||||||||
| Full Title: A 54-Week Treatment, Multicenter, Randomized, Double-Blind, Double-Dummy, Placebo and Active-Controlled, Parallel-Group Phase 2 Study to Assess the Efficacy and Safety of Brazikumab in Participants... | |||||||||||||
| Medical condition: Ulcerative Colitis | |||||||||||||
|
|||||||||||||
| Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
| Trial protocol: GB (GB - no longer in EU/EEA) DE (Completed) BE (Completed) FR (Completed) CZ (Prematurely Ended) ES (Prematurely Ended) BG (Prematurely Ended) AT (Prematurely Ended) HU (Prematurely Ended) IT (Prematurely Ended) RO (Completed) | |||||||||||||
| Trial results: View results | |||||||||||||
| EudraCT Number: 2017-003238-96 | Sponsor Protocol Number: I6T-MC-AMBG | Start Date*: 2018-10-15 | |||||||||||
| Sponsor Name:Eli Lilly and Company | |||||||||||||
| Full Title: A PHASE 3, MULTICENTER, RANDOMIZED, DOUBLE-BLIND, PARALLEL-ARM, PLACEBO-CONTROLLED MAINTENANCE STUDY OF MIRIKIZUMAB IN PATIENTS WITH MODERATELY TO SEVERELY ACTIVE ULCERATIVE COLITIS (LUCENT 2) | |||||||||||||
| Medical condition: Moderately to Severely Active Ulcerative Colitis | |||||||||||||
|
|||||||||||||
| Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
| Trial protocol: DE (Completed) GB (GB - no longer in EU/EEA) NL (Ongoing) LV (Completed) CZ (Completed) LT (Completed) ES (Completed) BE (Completed) HU (Completed) AT (Completed) SK (Completed) DK (Completed) HR (Completed) IT (Completed) RO (Ongoing) | |||||||||||||
| Trial results: View results | |||||||||||||
| EudraCT Number: 2011-002818-37 | Sponsor Protocol Number: CCX115393 | Start Date*: 2012-02-15 | |||||||||||
| Sponsor Name:GlaxoSmithKline Research & Development Ltd [...] | |||||||||||||
| Full Title: A phase II, 20-week, multi-centre, randomised, double-blind, placebo-controlled, parallel group proof of concept study to investigate the efficacy and safety of GSK1605786 for treatment of patients... | |||||||||||||
| Medical condition: Subjects with Active Ulcerative Colitis. | |||||||||||||
|
|||||||||||||
| Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
| Trial protocol: BE (Completed) GB (Completed) NL (Prematurely Ended) | |||||||||||||
| Trial results: View results | |||||||||||||
| EudraCT Number: 2006-004303-19 | Sponsor Protocol Number: BSX - 001 | Start Date*: 2007-04-25 | |||||||||||
| Sponsor Name:Cerimon Pharmaceuticals, Inc. | |||||||||||||
| Full Title: A Randomized, Double-Blind, Placebo-Controlled Evaluation of the Safety, Efficacy, and Pharmacokinetics of Multiple Doses of Basiliximab, with Concomitant Corticosteroids, in Steroid-Refractory Ulc... | |||||||||||||
| Medical condition: Steroid-refractory ulcerative colitis | |||||||||||||
|
|||||||||||||
| Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
| Trial protocol: GB (Completed) BE (Completed) CZ (Prematurely Ended) SK (Completed) | |||||||||||||
| Trial results: (No results available) | |||||||||||||
| EudraCT Number: 2006-003604-19 | Sponsor Protocol Number: IM101108 | Start Date*: 2007-08-06 | |||||||||||
| Sponsor Name:Bristol-Myers Squibb International Corporation | |||||||||||||
| Full Title: A Phase III, Multi-Center, Randomized, Placebo-Controlled Study to Evaluate the Clinical Efficacy and Safety of Induction and Maintenance Therapy with Abatacept in Subjects with Active Ulcerative C... | |||||||||||||
| Medical condition: ULCERATIVE COLITIS,NOS | |||||||||||||
|
|||||||||||||
| Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
| Trial protocol: DE (Prematurely Ended) FR (Completed) IE (Prematurely Ended) BE (Completed) GB (Prematurely Ended) CZ (Prematurely Ended) PL (Prematurely Ended) IT (Prematurely Ended) | |||||||||||||
| Trial results: View results | |||||||||||||
| EudraCT Number: 2007-006692-37 | Sponsor Protocol Number: VitDIBD1 | Start Date*: 2008-04-10 | ||||||||||||||||
| Sponsor Name:Imperial College London | ||||||||||||||||||
| Full Title: The Immunomodulatory Role of Vitamin D in Inflammatory Bowel Disease (IBDVit): IBDVit1 - Trial of Adjuvant Vitamin D with Corticosteroids in Active Crohn’s Disease; IBDVit2 - Trial of Adjuvant Vita... | ||||||||||||||||||
| Medical condition: IBDVit1 - Active Crohn's Disease IBDVit2 - Active Crohn's Disease IBDVit3 - Crohn's Disease in remission / Ulcerative Colitis in remission | ||||||||||||||||||
|
||||||||||||||||||
| Population Age: Adults, Elderly | Gender: Male, Female | |||||||||||||||||
| Trial protocol: GB (Prematurely Ended) | ||||||||||||||||||
| Trial results: View results | ||||||||||||||||||
| EudraCT Number: 2015-004724-62 | Sponsor Protocol Number: UCDCRC/15/007 | Start Date*: 2015-12-22 | |||||||||||
| Sponsor Name:UCD | |||||||||||||
| Full Title: Golimumab (GLM) dose Optimisation to Adequate Levels to Achieve Response in Colitis. (GOAL-ARC) | |||||||||||||
| Medical condition: Ulcerative Colitis | |||||||||||||
|
|||||||||||||
| Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
| Trial protocol: IE (Prematurely Ended) | |||||||||||||
| Trial results: View results | |||||||||||||
| EudraCT Number: 2006-003398-28 | Sponsor Protocol Number: C0524T17 | Start Date*: 2007-11-15 | |||||||||||
| Sponsor Name:Centocor BV | |||||||||||||
| Full Title: A Phase 2/3 Multicenter, Randomized, Placebo-controlled, Double blind Study to Evaluate the Safety and Efficacy of Golimumab Induction Therapy, Administered Subcutaneously, in Subjects with Moderat... | |||||||||||||
| Medical condition: Ulcerative Colitis (UC) | |||||||||||||
|
|||||||||||||
| Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
| Trial protocol: DE (Completed) HU (Completed) AT (Completed) BE (Completed) FR (Completed) LT (Completed) LV (Completed) NL (Completed) DK (Completed) SE (Completed) BG (Completed) SK (Completed) CZ (Completed) | |||||||||||||
| Trial results: View results | |||||||||||||
| EudraCT Number: 2021-003702-42 | Sponsor Protocol Number: B7981058 | Start Date*: 2022-05-17 | |||||||||||
| Sponsor Name:Pfizer Inc. | |||||||||||||
| Full Title: AN INTERVENTIONAL PHASE 3, RANDOMIZED, DOUBLE-BLIND, PLACEBO CONTROLLED, PARALLEL GROUP STUDY OF THE EFFICACY AND SAFETY OF RITLECITINIB (PF-06651600) IN ADULT PARTICIPANTS WITH MODERATELY TO SEVER... | |||||||||||||
| Medical condition: Moderate to Severe Ulcerative Colitis (UC) | |||||||||||||
|
|||||||||||||
| Population Age: Adults | Gender: Male, Female | ||||||||||||
| Trial protocol: ES (Prematurely Ended) | |||||||||||||
| Trial results: (No results available) | |||||||||||||
| EudraCT Number: 2010-020448-37 | Sponsor Protocol Number: ENC-0303-CL-203 | Start Date*: 2011-12-21 | |||||||||||
| Sponsor Name:Enceladus Pharmaceuticals | |||||||||||||
| Full Title: Randomized placebo-controlled multicenter exploratory Phase IIA study to assess the safety and efficacy of PEG-liposomal prednisolone sodium phosphate (Nanocort) in subjects with active ulcerative ... | |||||||||||||
| Medical condition: Active Ulcerative Colitis | |||||||||||||
|
|||||||||||||
| Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
| Trial protocol: NL (Prematurely Ended) BE (Completed) | |||||||||||||
| Trial results: (No results available) | |||||||||||||
| EudraCT Number: 2008-007952-90 | Sponsor Protocol Number: LT-02-UC-01 | Start Date*: 2009-11-17 | |||||||||||
| Sponsor Name:Lipid Therapeutics GmbH | |||||||||||||
| Full Title: A randomized, multi-center, doubleblind, parallel group, placebocontrolled, phase IIb, dose ranging study to investigate the efficacy and safety of LT-02 in patients with mesalazine-refractory ulce... | |||||||||||||
| Medical condition: Patients with ulcerative colitis (UC) according to European Crohn's and Colitis Organisation (ECCO) consensus; Simple Clinical Colitis Activity Index (SCCAI) ≥5 and SCCAI subscore for “blood in sto... | |||||||||||||
|
|||||||||||||
| Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
| Trial protocol: DE (Completed) LT (Completed) | |||||||||||||
| Trial results: (No results available) | |||||||||||||
| EudraCT Number: 2017-000572-28 | Sponsor Protocol Number: SHP647-302 | Start Date*: Information not available in EudraCT | |||||||||||
| Sponsor Name:Shire Human Genetic Therapies, Inc. | |||||||||||||
| Full Title: A Phase 3 Randomized, Double-blind, Placebo-controlled, Parallel-group Efficacy and Safety Study of SHP647 as Induction Therapy in Subjects with Moderate to Severe Ulcerative Colitis (FIGARO UC 302) | |||||||||||||
| Medical condition: Ulcerative Colitis | |||||||||||||
|
|||||||||||||
| Population Age: Adolescents, Under 18, Adults, Elderly | Gender: Male, Female | ||||||||||||
| Trial protocol: IE (Completed) HU (Completed) SK (Completed) BG (Completed) GR (Completed) BE (Completed) ES (Prematurely Ended) PT (Completed) FR (Completed) | |||||||||||||
| Trial results: View results | |||||||||||||
Subscribe to this Search
To subscribe to the RSS feed for this search click here
.
This will provide an RSS feed for clinical trials matching your search that have been added or updated in the last 7 days.
To subscribe to the RSS feed for this search click here
.
This will provide an RSS feed for clinical trials matching your search that have been added or updated in the last 7 days.
| Download Options: | |
|---|---|
| Number of Trials to download: | |
| Download Content: | |
| Download Format: | |
| Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial. | |
Query did not match any studies.